Weekly Digest - 15-21 Apr 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 15-21 Apr 2023
April 16, 2023: Atezolizumab (IV) + Bevacizumab (IV) / HCC / Genentech / Roche: Phase 3 IMbrave050 study demonstrated reduced risk of cancer recurrence in patients
Genentech reported positive data from AACR 2023 for Phase 3 IMbrave050 trial investigating Atezolizumab + Bevacizumab compared to active surveillance in patients with HCC
- Tecentriq® (atezolizumab) + Avastin® (bevacizumab) demonstrated a statistically significant improvement in recurrence-free survival in people with HCC at high risk of disease recurrence following liver resection or ablation with curative intent
- Atezo + Bev reduced the risk of cancer returning by 28%, compared with active surveillance after median follow-up of 17.4 months
- Safety was consistent with the well-established safety profile of each therapeutic treatment
